Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

Bedtime dosing with antihypertensive medication yields better nocturnal blood pressure control and improved circadian rhythm.

HealthDay News — Delays in diagnosis of hypertension are common and associated with delays in treatment initiation, according to a study published online July 14 in JAMA Network Open.

Background Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation ...